Bulgaria to Ban Sale of Non-Tobacco Flavored Products in 2024

Regulations by 2FIRSTS.ai
Dec.15.2023
Bulgaria to Ban Sale of Non-Tobacco Flavored Products in 2024
Bulgaria will ban all heated tobacco products, excluding tobacco flavor, from January 1st, 2024, to comply with EU regulations.

According to recent reports by Bulgarian media outlet Novinite, all heated tobacco products, excluding tobacco-flavored ones, will cease to be sold in Bulgaria starting from January 1, 2024. This regulation was established through the revision of the Tobacco and Tobacco Products Act by legislators without causing any controversy.

 

The recently approved amendment to the tobacco and tobacco products law by the House of Representatives has established this provision without any debate. This move is in response to a directive from the European Commission, non-compliance of which could result in criminal prosecution against Bulgaria. The aim of these amendments is to reduce the appeal of heated tobacco products, particularly by eliminating fragrance options.

 

In addition, each package of heated tobacco products must display warnings, emphasizing the associated risks during use.

 

According to the updated legislation, the Bulgarian Ministry of Economy and Industry will be responsible for banning additives in tobacco products that have significantly increased toxicity, addictiveness, or risks of cancer, mutation, or reproductive toxicity.

 

These legislative amendments await formal announcement in the national gazette published by the government.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts’ Nine Global Turning Points: How 2025 Reshaped the Nicotine Industry
2Firsts’ Nine Global Turning Points: How 2025 Reshaped the Nicotine Industry
In 2025, the global nicotine industry reached a critical turning point. Regulatory realignment, category shifts, capital repositioning and technological intervention unfolded in parallel, loosening old structures while new ones took shape. 2Firsts reviews nine pivotal events that reshaped the industry’s trajectory.
Jan.14
Arizona Moves to Tighten Vape Supply-Chain Enforcement, Targeting Illicit Products
Arizona Moves to Tighten Vape Supply-Chain Enforcement, Targeting Illicit Products
Arizona state Sen. Shawnna Bolick introduced SB 1397 to curb illicit vapes by tracing product origins, intercepting illegal shipments, and cracking down on retailers that violate state law. The proposal would require manufacturers to hold a state license to sell in Arizona, with fines up to $10,000 for unlicensed sales.
Jan.30 by 2FIRSTS.ai
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
Belgium: BAT plans to cut 51 jobs at Groot-Bijgaarden site
British American Tobacco (BAT) has announced plans to cut 51 jobs at its Groot-Bijgaarden facility in Belgium, disclosed during a special works council meeting.
Jan.15 by 2FIRSTS.ai
Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia proposes extending voluntary labeling pilot for reusable e-cigarettes to Aug. 31, 2026
Russia’s Ministry of Industry and Trade has proposed extending a voluntary labeling pilot covering reusable e-cigarettes and similar personal electric vaporizing devices until August 31, 2026. A draft government decree has been published on the unified portal for posting drafts of normative legal acts.
Jan.22 by 2FIRSTS.ai
Vietnam Decree 371: vaping and heated tobacco use fined up to $190
Vietnam Decree 371: vaping and heated tobacco use fined up to $190
Vietnam’s Government Decree 371, effective December 31, 2025, stipulates that users of e-cigarettes and heated tobacco products will be fined VND 3–5 million (about $114–$190) and required to destroy the products. The decree also provides that individuals who allow use at premises they own or manage will be fined VND 5–10 million (about $190–$380), with fines doubled for organizations.
Jan.04 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11